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A B S T R A C T
Background and objective: In sub-Saharan Africa, data on prevalence, risk factors and pathobiology of carotid
atherosclerosis are scarce. We aimed to investigate the relationship between biomarkers of endothelial dys-
function and carotid atherosclerosis.
Methods: Carotid ultrasound was performed in 66 patients. Plasma concentration of ICAM-1, PAI-1, VEGF, and
soluble thrombomodulin were measured by ELISA. A univariable logistic regression analysis was performed to
study the relationship between carotid atherosclerosis, biomarkers of endothelial dysfunction, and various de-
mographic and clinical parameters of the participants.
Results: The mean age of the participants was 58.7 years (95% CI: 54.4–63.1). Carotid atherosclerosis was di-
agnosed in 39.4% (95% CI: 27.6–52.2). In the univariable logistic regression, the following factors were asso-
ciated with carotid atherosclerosis: age > 45 years (OR = 12.0, 95% CI: 1.4–98.8, p = .02), hypertension
(OR = 3.8, 95% CI: 1.2–12.1, p = .02), and high-level of soluble thrombomodulin (OR = 3.4, 95% CI: 1.2–10.0,
p = .02).
Conclusions: There is an association between high levels of soluble thrombomodulin and carotid atherosclerosis
in Malawian adults. Further studies with a larger sample size are needed to confirm our findings in other African
populations.
1. Introduction
Several studies carried out in Western countries have established
that endothelial dysfunction, triggered by various cardiovascular risk
factors, is the primum movens of the arterial remodelling process
leading to atherosclerosis and then atherothrombotic events [1,2]. In
sub-Saharan Africa, data on prevalence, risk factors and pathobiology
of carotid atherosclerosis are scarce. To address this knowledge gap, we
have conducted several prospective studies in Malawi, a country
with> 10% prevalence of HIV [3–6]. In one study, we showed that
endothelial dysfunction persists despite antiretroviral therapy and
could, therefore, contribute to the development of atherosclerosis [5].
In a subsequent study, we reported a 39.4% prevalence of carotid
atherosclerosis in a sample of 66 patients presenting with an acute
stroke-like syndrome [7]. Plasma samples were also collected from the
patients to investigate the relationship between biomarkers of en-
dothelial dysfunction and carotid atherosclerosis. Here, we present and
discuss the findings of these complimentary analyses.
2. Methods
2.1. Selection of patients and ultrasound assessment
Participants were recruited consecutively from April to August 2017
at the Queen Elizabeth Central Hospital which is the largest referral
hospital in Malawi. The presence of any cardiovascular risk factor was
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recorded according to previously reported definitions [7].
Carotid ultrasound examination was performed on the day of en-
rolment (JKT) using the CX50 portable ultrasound device (Philips,
Amsterdam, NL). Details of the examination protocol and criteria for
the interpretation of findings were reported previously [7]. Briefly, the
examination comprised a semi-automated assessment of the carotid
intima-media thickness (cIMT) and a grading of any existing stenosis.
Carotid atherosclerosis was defined as abnormal intima-media thick-
ness or presence of carotid plaque with or without stenosis.
In order to define abnormal cIMT, the following age-specific cut-offs
were applied: 0.60 mm (30–39 years old), 0.65 mm (40–49 years old),
0.70 mm (50–59 years old), 0.75 mm (60–69 years old), and 0.80 mm
(≥70 years old). In the absence of reference values specific to African
populations, the reference cut-off in each age category was chosen close
to the upper limit of the 95% confidence interval of the mean cIMT for
participants without cardiovascular risk factors enrolled in the PARC
study (Paroi Artérielle et Risque Cardiovasculaire) [8]. Results of the
PARC study suggest that the normal aging of the arterial vessel wall is
associated with intima-media thickening by approximately 0.5 mm per
decade. In patients with cardiovascular risk factors, the cIMT is typi-
cally higher that the indicated cut-off in each age category and is de-
pendent on the number of cardiovascular risk factors as illustrated in
the Mannheim consensus guidelines [9].
2.2. Measurement of biomarkers of endothelial dysfunction
We used ELISA kits from Abcam ® (Abcam plc, Cambridge, United
Kingdom) to measure the plasma concentrations of biomarkers of en-
dothelial activation (intercellular adhesion molecule, ICAM-1), en-
dothelial damage (plasminogen activator inhibitor 1, PAI-1), angio-
genesis (vascular endothelial growth factor, VEGF), and coagulopathy
(soluble thrombomodulin, sTM). SimpleStep® ELISA kits were used for
ICAM-1, PAI-1, and sTM while the standard kit was used for VEGF. All
samples were run in duplicates and samples with an individual coeffi-
cient of variability (CV) greater than 25% were retested in duplicates.
All the ELISA tests were performed according to the manufacturer’s
instructions with exception of the washing steps that were performed
with an automated washer (ASYS Atlantis®, Biochrom Ltd., Cambridge,
UK) using a mixture of phosphate buffer saline and Tween 20 (0.05% v/
v). The plates were read at 450 nm using an automated microplate
reader (EZ Read®, Biochrom Ltd., Cambridge, UK). The standard curves
were built using 4-parameter logistic regression. The mean intra-assay
CV for ICAM-1, PAI-1, VEGF, and sTM was 3.3%, 3.2%, 8.0%, and 3.1%
respectively (accepted value< 10%). The mean inter-assay CV for
ICAM-1, PAI-1, VEGF, and sTM was 4.1%, 4.1%, 9.0%, and 2.8% re-
spectively (accepted value< 15%).
2.3. Statistical analysis
Participants' demographic and clinical parameters were summarized
as proportions and means with 95% confidence interval for categorical
and numerical variables, respectively. The relationship between plasma
levels of biomarkers of endothelial dysfunction and cIMT was explored
using the Spearman rank correlation test.
A univariable logistic regression analysis was performed to study
the relationship between carotid atherosclerosis (dependent variable)
and various demographic and clinical parameters of the participants.
Following the approach in our previous publications [5,6], age was
dichotomized at 45 years while biomarkers were dichotomized at the
third tertile of the distribution of plasma concentration values (low
versus high level). A multivariable analysis was not performed due to
the small sample size. All statistical tests were two-tailed and statistical
significance was defined as p ≤ .05. Analyses were performed using the
software STATA (version 13, StataCorp, College Station, TX, USA).
3. Results
The mean age of the participants was 58.7 years (95% CI:
54.4–63.1). There were 22 HIV-positive patients and 77.3% were on
antiretroviral therapy. HIV+ cases were younger (mean age 43.6
versus 66.3, p < .001) and their mean CD4+ T cell count was 223/
mm3. There was no difference in the levels of biomarkers between HIV-
positive and HIV-negative patients. The baseline characteristics of the
participants are summarized in Table 1.
There was no correlation between the plasma concentration of the
biomarkers of endothelial dysfunction and the value of cIMT (Spearman
rank correlation coefficient of −0.24, −0.03, 0.11, 0.11 for ICAM-1,
PAI-1, sTM, and VEGF, respectively).
In the univariable logistic regression (Table 2), the following factors
were associated with carotid atherosclerosis: age > 45 years
(OR = 12.0, 95% CI: 1.4–98.8, p = .02), hypertension (OR = 3.8, 95%
CI: 1.2–12.1, p = .02), and high-level of soluble thrombomodulin
(OR = 3.4, 95% CI: 1.2–10.0, p = .02).
4. Discussion
This study is the first to investigate the relationship between bio-
markers of endothelial dysfunction and carotid atherosclerosis in sub-
Saharan Africa. The association between high levels of soluble throm-




Yes (n = 26) No (n = 40)
Age (years) 63.0 (57.7–68.2) 56.1 (49.7–62.4)
Age > 45 years 25 (96.2) 27 (67.5)
Men 13 (50.0) 15 (37.5)
HIV positive 7 (27.0) 15 (37.5)
On ART 7 (26.9) 10 (25.0)
Smoking 3 (11.5) 5 (12.5)
Alcohol consumption 4 (15.4) 9 (22.5)
Hypercholesterolemia 3 (11.5) 0 (0.0)
Hypertension 21 (80.8) 21 (52.5)
Diabetes mellitus 5 (19.2) 6 (15.0)
Waist-hip ratio 0.9 (0.9–1.0) 0.9 (0.8–0.9)
CD4+ count 472.3 (377.7–566.9) 421.2 (320.2–522.2)
ICAM-1 (ng/mL) 377.4 (244.2–510.6) 404.7 (268.4–540.9)
PAI-1 (ng/mL) 43.0 (26.8–59.2) 49.3 (31.0–67.5)
sTM (ng/mL) 8.1 (5.6–10.6) 6.2 (5.1–7.4)
VEGF (pg/mL) 12.8 (0.0–26.7) 4.4 (0.9–8.0)
a Data are presented as N (%) or mean (95%CI).
Table 2
Univariable analysis of factors associated with carotid atherosclerosis.
Characteristica Univariable analysis
OR 95% CI p
HIV infection 0.6 0.2–1.8 0.38
Age > 45 12.0 1.4–98.8 0.02
Male 1.6 0.6–4.5 0.32
Hypertension 3.8 1.2–12.1 0.02
Diabetes mellitus 1.3 0.4–5.0 0.65
Smoking 0.9 0.2–4.2 0.91
Waist-hip ratio (3rd tertile) 1.9 0.7–5.5 0.22
ART started 1.1 0.4–3.4 0.86
High level of ICAM-1 0.8 0.3–2.4 0.72
High level of PAI-1 1.1 0.4–3.1 0.86
High level of sTM 3.4 1.2–10.0 0.02
High level of VEGF 1.8 0.6–5.5 0.32
a There were 3 patients with hypercholesterolemia and they all had carotid
atherosclerosis.
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Western populations [10,11]. Soluble thrombomodulin is an en-
dothelial membrane glycoprotein also known as CD141. It is a marker
of endothelial injury and higher plasma levels have been associated
with other risk factors of atherosclerosis, notably age and hypertension
[12]. In this study, patients with carotid atherosclerosis had a higher
mean age and a higher prevalence of hypertension, which could con-
tribute to the association between high levels of soluble thrombomo-
dulin and carotid atherosclerosis. Due to the small sample size of this
exploratory study, we could not reliably assess the independence of the
association in a multivariable analysis. Further studies with a larger
sample size are, therefore, needed to confirm our findings in African
populations and investigate the performance of biomarkers of en-
dothelial dysfunction as predictors of cardiovascular events. The small
sample size likely also explains why our analysis did not show an as-
sociation between carotid atherosclerosis and other established drivers
of endothelial dysfunction and atherosclerosis, notably smoking, dia-
betes mellitus, adiposity, and HIV infection [13–16]. Specifically, for
HIV-positive patients who are younger, longitudinal studies are needed
to investigate if the persistence of HIV-induced endothelial dysfunction
has a significant and independent impact on the incidence of carotid
atherosclerosis and whether antiretroviral or anti-inflammatory drugs
are useful to prevent its progression and cerebrovascular consequences.
Such studies should ideally be performed on large sample size popu-
lations and follow international consensus recommendations for the
assessment of subclinical and clinical atherosclerosis in order to avoid
generating more heterogeneous or contradictory results [17].
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